FDA approves AstraZeneca treatment for cases reacting badly to vaccines

By Akshay Kedari  | Date: 2021-12-09

FDA approves AstraZeneca treatment for cases reacting badly to vaccines

The U.S. FDA has reportedly issued an emergency use authorization of synthetic AstraZeneca antibodies for the prevention of Covid-19 infections in people who have had a severe reaction to vaccines. This is the first time the U.S. health authority has granted emergency approval for such a purely preventative treatment.

According to the FDA, the drug Evusheld isn’t a replacement for vaccination in those for whom COVID-19 vaccination is advised and can only be used by patients with a weaker immune system or who are unable to be vaccinated due to medical reasons such as a severe allergic reaction. In such cases, the drug can be provided for people who are aged 12 or above.

For those unaware, Evusheld is a drug that combines two synthetic antibodies (tixagevimab and cilgavimab) and is administered as two consecutive intramuscular injections. These antibodies aid the immune system in combating the virus by attacking the virus's spike protein, which permits it to access and infect cells. 

As per a statement given by the FDA, it may be useful for pre-exposure protection for six months and cannot be given to someone who is already infected with the virus, though AstraZeneca is testing it for this purpose.

The drug is known to have possible side effects like allergic reactions, bleeding from the injection site, headaches, and lethargy.

The FDA's approval was based on a clinical trial that included unvaccinated adults over the age of 59, suffering from chronic diseases, or those who were at high risk of infection. The result showed that the therapy reduced the probability of developing COVID-19 by 77%.

In the United States, two antibody cocktails developed by Regeneron and Eli Lilly are presently approved for the prevention of infection, but only in those who have recently been exposed to the virus or who have a high risk of being exposed to the disease.

Source Credit:

https://www.ndtv.com/world-news/us-authorizes-astrazeneca-evusheld-drug-for-covid-treatment-in-some-cases-2643322

About Author

Akshay Kedari     aeresearch.net

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More >>

More News By Akshay Kedari

Instagram users can now delete their accounts on all Apple devices

Instagram users can now delete their accounts on all Apple devices

By Akshay Kedari

To comply with Apple’s App Store guidelines, popular social media platform Instagram has now added account deletion support to iOS devices. The iPhone maker's store policy notably instructs that all apps that allow users to create accounts ...

Tesla lays off 200 hourly workers as it closes its California office

Tesla lays off 200 hourly workers as it closes its California office

By Akshay Kedari

Tesla Inc. reportedly closed its San Mateo, California office to expedite cost-cutting and has let go nearly 200 workers who functioned on its autopilot driver-assistant system. Most of these employees were compensated on an hourly basis. Earlier ...

Around 2,900 Ford Lightning pickups recalled over software-linked issue

Around 2,900 Ford Lightning pickups recalled over software-linked issue

By Akshay Kedari

The recall covers 220 units of the electric pickup trucks in Canada and 2,666 units in the US. Ford has refused to accept any more orders and declared the EV sold out for 2022. Ford Motor Company has reportedly recalled the first batch of ...

Coca-Cola ranked the most powerful brand in U.S., as per the BSI score

Coca-Cola ranked the most powerful brand in U.S., as per the BSI score

By Akshay Kedari

The Coca-Cola Company, an American multinational beverage corporation, has reportedly secured a Brand Strength Index (BSI) score of 93.3 out of 100, making it the strongest brand in the USA, according to a TradingPlatforms.com analysis of the iconic ...

FDA to order Juul Labs to pull its e-cigarettes from the United States

FDA to order Juul Labs to pull its e-cigarettes from the United States

By Akshay Kedari

The U.S. FDA (Food and Drug Administration) is reportedly planning to instruct Juul Labs Inc. to stop supplying its e-cigarettes in the country. Shares of Altira, which owns a 35% stake in Juul Labs, fell to 8.5% after the latest development. For ...